Rapivab

(Peramivir)

Phase 2Small molecule

BBioCryst Pharmaceuticals

Rapivab is one of 53 small molecule programs targeting Respiratory tract infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Respiratory Tract InfectionActive, not recruiting

InfluenzaActive, not recruiting

Respiratory Tract InfectionPhase 2/Phase 3

Active, not recruiting

InfluenzaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Rapivab

BBioCryst Pharmaceuticals

Phase 2

13 2

Fluzone

GSK

Preclinical

37 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Crestor

AstraZeneca

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 10

Afluria

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Influenza

NCT05648448

Clinical

Trials by Indication[1]

Influenza13 trials

A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.

Terminated·BBioCryst Pharmaceuticals·Phase 3·NCT01224795·1 enrolled

A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

Completed·BBioCryst Pharmaceuticals·Phase 2·NCT00705406·405 enrolled

Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza

Completed·BBioCryst Pharmaceuticals·Phase 3·NCT02369159·137 enrolled

Show 10 more trials

ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir

Completed·JJohns Hopkins University·Phase 4·NCT02609399·180 enrolled

A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Recruiting·UUniversity of Oxford·Phase 2·NCT05648448·3,000 enrolled

Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza

Terminated·BBioCryst Pharmaceuticals·Phase 3·NCT00610935·82 enrolled

Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

Completed·BBioCryst Pharmaceuticals·Phase 3·NCT00957996·234 enrolled

Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza

Completed·BBioCryst Pharmaceuticals·Phase 3·NCT02635724·74 enrolled

Safety and Dose Study of Peramivir for Influenza Treatment

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00297050·100 enrolled

Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT01063933

Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.

Completed·BBioCryst Pharmaceuticals·Phase 2·NCT00419263·344 enrolled

Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza

Completed·BBioCryst Pharmaceuticals·Phase 2·NCT00453999·137 enrolled

Intramuscular Peramivir for the Treatment of Uncomplicated Influenza

Withdrawn·BBioCryst Pharmaceuticals·Phase 3·NCT00486980

Respiratory tract infection1 trial

Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections

Completed·—·Phase 2/3·NCT02665351·16 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 19, 2014

RAPIVAB

NDA NDA206426

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Peramivir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peramivir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peramivir. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA206426). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Rapivab. U.S. Food & Drug Administration.
[6]
SEC EDGAR — BioCryst Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBioCryst Pharmaceuticals

Patent Landscape[5]

Patent Cliff

Feb 12, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10391075Feb 12, 2027

8778997May 7, 2027

Rapivab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Influenza13 trials

Respiratory tract infection1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News